ERBB2 and triple-negative breast carcinoma: Among them, 310 (38.18%) were Luminal A subtype, 271 (33.37%) were Luminal B, 176 (21.68%) were HER2 positive, and 55 (6.77%) were triple-negative breast cancer (TNBC).